Sugi Predict

Sugi Predict / Compounds / SCHEMBL4488706

SCHEMBL4488706

SCHEMBL4488706

Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3Cl)c12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 14/20 0.75
▸ KIT P10721 11/20 0.75
▸ FLT3 P36888 10/20 0.75
▸ FLT1 P17948 7/20 0.60
▸ TEK Q02763 4/20 0.60
▸ AURKA O14965 7/20 0.59
▸ MAP4K4 O95819 6/20 0.59
▸ MARK3 P27448 6/20 0.59
▸ AXL P30530 6/20 0.59
▸ LIMK1 P53667 6/20 0.59
▸ CSNK1G2 P78368 6/20 0.59
▸ MAP4K2 Q12851 6/20 0.59
▸ STK3 Q13188 6/20 0.59
▸ ROCK1 Q13464 6/20 0.59
▸ NTRK2 Q16620 6/20 0.59
▸ MARK2 Q7KZI7 6/20 0.59
▸ HIPK4 Q8NE63 6/20 0.59
▸ SLK Q9H2G2 6/20 0.59
▸ CLK4 Q9HAZ1 6/20 0.59
▸ MKNK2 Q9HBH9 6/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466205 0.90 KDR (0.77) KDRKITFLT3FLT1TEK
SCHEMBL4477343 0.88 KIT (0.75) KDRKITFLT3FLT1TEK
SCHEMBL4478281 0.88 KIT (0.78) KDRKITFLT3FLT1TEK
SCHEMBL4467381 0.88 KIT (0.82) KDRKITFLT3FLT1TEK
SCHEMBL4467337 0.87 KDR (0.78) KDRKITFLT3FLT1TEK
SCHEMBL4476878 0.86 KDR (0.77) KDRKITFLT3FLT1TEK
SCHEMBL4474210 0.86 KDR (1.00) KDRKITFLT3FLT1TEK
SCHEMBL4720107 0.82 MAP4K4 (0.74) KDRKITFLT3FLT1TEK
SCHEMBL4469648 0.81 KDR (0.78) KDRKITFLT3FLT1TEK
SCHEMBL4466145 0.80 KDR (0.79) KDRKITFLT3FLT1TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885KIT 394/4885FLT3 29/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885KIT 361/4885FLT3 16/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885KIT 394/4885FLT3 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.